Old API Wind-down Ltd - Ordinary Shares ARLZQ

RE:Can Spec Pharma Survive Valeant's Collapse

[kuatolives]

Still not pretty to watch, but ARLZ might have a good opportunity to revive the sector as all of yosprala, vimovo and treximet were developed rather than purchased, and as for Yosprala, ARLZ has the opportunity to price the drug to what the market would find acceptable rather than find itself in the cross hairs of Clinton etc co. Valeant just needs to break up and go away.